Tempo Bioscience

The Many Faces of Phagocytes | Tempo Bioscience

Most of us were introduced to phagocytosis as a cellular event where dead host cells, microbial cells or their components, or other foreign bodies are engulfed and often destroyed by specialized cells known as phagocytes. During my undergraduate studies, phagocytosis was a small topic within immunology and macrophages were the crème de la crème of phagocytes, patrolling the body’s tissues for foreign invaders, much like security guards patrolling their territories.
Research Features

Uncovering new strategies to reduce TB susceptibility in HIV-infected individuals

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a serious cause of disease and mortality worldwide, especially in developing countries. Co-infection with the human immunodeficiency virus (HIV) aggravates this situation, and puts intense pressure on national healthcare services in sub-Saharan Africa, where up to 80% of TB patients are HIV-infected, and where TB is now the leading cause of death in HIV-infected individuals.
Research Features

A multistressor world: marine climate change and its effects on ocean life

Coastal marine ecosystems represent the most diverse and productive parts of the world’s oceans, providing a range of crucial ecosystem services such as food, protection, and recreation to humankind. Unfortunately, coastal ecosystems are threatened due to marine climate change, marked by three related and concomitant oceanic changes: warming, acidification (increased carbon dioxide levels), and declining oxygen levels.
Research Features

A two-pronged approach to reduce heart failure in childhood cancer survivors

Anthracyclines such as doxorubicin, daunomycin and darubicin belong to a class of chemotherapeutic drugs that is widely used to treat paediatric cancers. Advances in chemotherapy, other treatment strategies and supportive care have led to significant improvements in paediatric cancer outcomes, with current five-year survival rates exceeding 80%. Improved survival rates mean that there are now more than 400,000 long-term childhood cancer survivors in the U.S, and this number is steadily growing.
Load More Articles